To the full analysis
Buyback calculator for Enanta Pharmaceuticals
Enanta Pharmaceuticals stock: key metrics
ENTAEnanta Pharmaceuticals had an operating margin of −130.7% and a return on invested capital (ROIC) of −73.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2010 | 100.0% | 30.5% | 34.7% |
| 2011 | 100.0% | 60.4% | 55.7% |
| 2012 | 100.0% | 51.0% | 51.3% |
| 2013 | 100.0% | 28.2% | 30.0% |
| 2014 | 100.0% | 39.8% | 72.1% |
| 2015 | 100.0% | 77.2% | 49.1% |
| 2016 | 100.0% | 34.9% | 24.5% |
| 2017 | 100.0% | 23.9% | 17.2% |
| 2018 | 100.0% | 42.7% | 34.8% |
| 2019 | 100.0% | 17.9% | 22.6% |
| 2020 | 100.0% | −34.0% | −29.5% |
| 2021 | 100.0% | −112.9% | −81.4% |
| 2022 | 100.0% | −143.7% | −141.3% |
| 2023 | 100.0% | −173.2% | −169.0% |
| 2024 | 100.0% | −179.9% | −171.6% |
| 2025 | 93.0% | −130.7% | −125.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2010 | 0.0% | no data | 0.0% |
| 2011 | −17.7% | 105.6% | 89.3% |
| 2012 | 48.7% | 60.5% | 41.0% |
| 2013 | 8.7% | 11.4% | 8.2% |
| 2014 | 23.2% | 56.6% | 22.2% |
| 2015 | 33.4% | 104.5% | 32.1% |
| 2016 | 8.0% | 27.0% | 7.7% |
| 2017 | 5.9% | 23.3% | 5.4% |
| 2018 | 18.3% | 83.4% | 17.4% |
| 2019 | 10.0% | 34.5% | 9.5% |
| 2020 | −7.9% | −31.9% | −7.4% |
| 2021 | −19.8% | −71.9% | −17.9% |
| 2022 | −37.9% | −75.0% | −32.0% |
| 2023 | −61.7% | −28.9% | −28.9% |
| 2024 | −90.1% | −25.5% | −30.8% |
| 2025 | −100.0% | −73.5% | −29.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.